Vascular Neurosurgery Flashcards
Aneurysmal rebleed rate
0-24 h: 4%
0-2 wk: 20 %
0-6 mo: 50%
> 6 mo: 3%
Associated pathologies with aneurysmal formation
Hypertension
Endocarditis
Poly cystic kidney
Ehler-Donlas
Marfan syndrome
Moyamoya
Pseudoxanthoma elasticum
Aortic coarctation
AVM
Fibromuscular dysplasia
Vasculitis
NF1
ISUIA 1 (1 year rupture risk with unruptured aneurysm)
No previous bleed vs. previous bleed
0-10 mm: 0.05% vs 0.5%
10-24 mm: <1 % vs <1%
>24 mm: 6%
ISUIA 2 (Five-year rupture risk who is unruptured aneurysm)
CAVERNOUS ICA
<7 mm: 0%
7-12 mm: 0%
13-24 mm: 3%
>24 mm: 6.4%
ISUIA 2 (Five-year rupture risk who is unruptured aneurysm)
ANTERIOR CIRCULATION
<7 mm: 0% (1.5% if previous bleed)
7-12 mm: 2.6%
12-24 mm: 14.5%
>24 mm: 40%
ISUIA 2 (Five-year rupture risk who is unruptured aneurysm)
POSTERIOR CIRCULATION
<7 mm: 2.5% (3.5% if previous bleed)
7-12 mm: 14.5%
13-24 mm: 18.4%
>24 mm: 50%
% of aneurysm locations
30% Acom
25% Pcom
20% MCA bifurcation
8% ICA bifurcation
17% other locations
Imaging sensitivity CTA vs. MRI for aneurysm
> 5 mm : 95-100% vs 85-100%
<5 mm : 64-83% vs 56%
Fisher’s grade and vasospasm risk
Grade 1- No bleed (21%)
Grade 2- Diffuse or vertical layer < 1 mm thick (25 %)
Grade 3- Localized clot or vertical layer >1 mm thick (37 %)
Grade 4- ICH or IVH (31%)
Modified Fisher’s and Vasospasm risk
Grade 1: Focal or diffuse THIN SAH (24%)
Grade 2: Grade 1 + IVH (33%)
Grade 3: Focal of diffuse THICK SAH (33 %)
Grade 4: Grade 3 + IVH (40%)
What is Lindegaard’s ratio?
Velocity MCA:ICA
<3 : No vasospasm
3-6: Mild/moderate vasospasm
>6: Severe vasospasm
Mean MCA Velocity
<120 cm/s : No vasospasm
120-200 cm/s: Mild/moderate vasospasm
>200 cm/s: Severe vasospasm
Triple H therapy
Hypervolemia: CVP 10 cmH2O, P wedge 18 mmHg.
Hemodilution: Hct 30%
Hypertension: SBP up to 220 (in secured aneurysm)
ISAT trial primary outcome
Coiling is superior to clipping
At 1 year 24% of coiling patients were dependent/dead vs. 31% in clipping group (mRS 3-6)
Surgical options for fusiform aneurysm
- Wrapping
- Clip reconstruction
- Trapping (+/- distal revascularization)
How do you use PAPAVERINE for vessels in spasms.
Dip cottonoid with 30 mg in 9 ml saline, then place it on artery for 2 minutes.
What is Paine’s point
Used to do ventriculostomy to relax brain during aneurysmal clipping.
From sphenoid ridge: 2.5 cm up + 2.5 cm anterior.
4.5 cm deep
What is management of mycotic aneurysm
Antibiotics: IV for 6 wks then PO for 6 wks.
What is most common organism in mycotic aneurysm
Streptococcus viridan (44%)
Staph aureus (18%) : classic in endocarditis
AHA/ASA guidelines for spontaneous ICH
1.Hemostasis: correct coagulopathy.
2. DVT prophylaxis: intermittent pneumatic compression.
3. SBP< 140
4. Seizure control: patient with clinical seizures, patient with mental status change + seizures findings on EEG.
STICH 1
Inclusion criteria
Spontaneous ICH
-Arisen within 72 h
-At least 2 cm on CT scan
-GCS >=5/15
-No obvious underlying causes
Conclusion
Depends on ICH depth from cortical surface
>1cm or GCS <=8: surgical patients tend to do worse
<=1 cm: tend toward better outcomes but not significant.
STICH 2
Inclusion criteria
-ICH with 1 cm from cortical surface.
-ICH volume 10-100 ml
-Best GCS motor score 5-6 and eye score >= 2
-No IVH
-No obvious underlying cause.
-Presentation with 48h
Conclusion:
Possible survival advantage in early surgery (within 12 h) especially with GCS 9-12/5
Indications of stenting in carotid stenosis
-Contralateral ICA occlusion
-Hostile neck
-tandem lesion
-above C2
-medical comorbidities eg congestive heart failure, and stable, angina, recent myocardial infarction
Anterior choroidal artery stroke symptoms
3 H’s
Homonymous hemianopia
Hemianesthesia
Hemiparesis
Heubner artery stroke
Territory: Caudate + putamen, Anterior limb of IC
Symptoms: Aphasia, mild hemiparesis of face and arm
PICA stroke
Territory: lateral part of medulla
Symptoms: WALLENBERG SYNDROME
-Ipsilateral horner (descending sympathetic)
-Ipsilateral cerebellar signs (Inf cerebellar peduncle)
-Ipsilateral face sensory loss of pain and temperature (Spinal trigeminal nucleus and tract)
-Contralateral body sensory loss of pain and temperature (lateral spinothalamic tract)
-Dysphagia (Nucleus ambiguous)
-Vomiting, vertigo, nystagmus (Vestibular nuclei)
Basilar artery bifurcation or PCA
Territory: midbrain infarction
Weber’s syndrome
-Ipsilateral CN III palsy
-Contralateral hemiparesis
Symptoms of vertebral insufficiency
5 D’s
Dizziness
Decreased vision
Diplopia
Dysarthria
Drop attack
Contraindications for tPA in stroke
-Improving symptoms
-Heparin infusion within 48h
-GI or GU hemorrhage within past 21 days.
-Major surgery with past 14 days.
-ICH on CT/hx of ICH.
-Stroke or serious head injury in past 3 months.
-Arterial puncture at noncompressible in the previous 21 days.
-Thrombin inhibitors or Factor Xa inhibitors in the past 2 days.
-Sustained SBP > 185.
-Sustained DBP > 110.
-Serum glucose < 50 mg/dl or >400 mg/dl
Moyamoya disease presentation
Pediatric present with ISCHEMIC STROKE or TIA (80%)
Young adult present with HEMORRHAGE (60%)
Headache
Seizures
Neurological deficits or cognitive decline
Involvement of heart and kidney
What is findings of Moyamoya disease in DSA/MRI/CT
DSA: puff of smoke
MRI: Multiple flow-void in basal ganglia
CT: multiple punctate dots in basal ganglia
Suzuki stages of Moyamoya disease
I: bilateral stenosis of suprasellar ICA.
II: dilation of ACA, MCA, PCA, collateral vessels at brain base.
III: progression of ICA stenosis and moyamoya vessels.
IV: progressive occlusion of circle of Willis and PCA, reduction of moyamoya vessels, presence of extracranial collateral.
V: Worsening of stage IV:
VI: no major cerebral artery or moyamoya vessels, extensive collateral from ECA.
What are indications of surgical management in Moyamoya disease?
-Presence of mass effect from clot
-Suzuki stage II-IV
-Patients with recurrent or progressive ischemic events in good neurological condition
What is surgical treatment of choice in moyamoya disease
STA-MCA bypass (direct revascularization)
Timing of surgery for Moyamoya disease
> 2 m after the most recent symptomatic event